4-Amino-5-(2-methoxy-phenyl)-4H-[1,2,4]triazole-3-thiol, 95.0%, 1g

(1S)-1-[5-(TRIFLUOROMETHYL)(2-PYRIDYL)]ETHYLAMINE, 95.0%, 100mg

3,3-Dimethylmorpholine;hydrochloride, 97%, 5g

N-ethyl-2-(1H-1,2,3-triazol-1-yl)ethan-1-amine hydrochloride, 95.0%, 500mg

[1-(2,2,2-Trifluoroethyl)-1H-imidazol-5-yl]methanamine hydrochloride, 1g

Matraces de doble cuello con fondo redondo y cuello lateral paralelo, 250 ml, 29/32, 1 Pieza

(S)-1-(3-Chloro-2-fluorophenyl)ethanamine hydrochloride, 95.0%, 5g

2,5-Diphenyloxazole, 98.0%, 500g

(2S,4S)-4-(tert-butoxy)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidine-2-carboxylic acid, 95.0%, 100mg

N-bromosuccinimida, mínimo 98 %, para síntesis, 500 g, envase de vidrio

D-(+)-Glucosamine Hydrochloride>98.0%(T)25g

4-Chloro-1H-pyrrolo[2,3-b]pyridin-2(3H)-one, 95.0%, 5g

Manguera de conexión HPLC interior x exterior Ø 1,6 x 3,2 mm (pulgadas x pulgadas), 100 mm, 1 pieza